CN1820748A - Levo-ornidazole freeze-dried powder injection - Google Patents
Levo-ornidazole freeze-dried powder injection Download PDFInfo
- Publication number
- CN1820748A CN1820748A CN 200510102377 CN200510102377A CN1820748A CN 1820748 A CN1820748 A CN 1820748A CN 200510102377 CN200510102377 CN 200510102377 CN 200510102377 A CN200510102377 A CN 200510102377A CN 1820748 A CN1820748 A CN 1820748A
- Authority
- CN
- China
- Prior art keywords
- ornidazole
- dried powder
- injection
- powder injection
- freezing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 51
- 239000007924 injection Substances 0.000 title claims abstract description 51
- 239000000843 powder Substances 0.000 title claims abstract description 37
- IPWKIXLWTCNBKN-ZCFIWIBFSA-N (2s)-1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol Chemical compound CC1=NC=C([N+]([O-])=O)N1C[C@H](O)CCl IPWKIXLWTCNBKN-ZCFIWIBFSA-N 0.000 title claims abstract description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 235000011187 glycerol Nutrition 0.000 claims abstract description 3
- 229960002313 ornidazole Drugs 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000003756 stirring Methods 0.000 claims description 19
- 239000008215 water for injection Substances 0.000 claims description 19
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 239000006184 cosolvent Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 238000011082 depyrogenation Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- -1 hydroxyethyl- Chemical group 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 238000012859 sterile filling Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 claims 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 35
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000010792 warming Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000004411 aluminium Substances 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000003103 anti-anaerobic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LRWZZZWJMFNZIK-NFJMKROFSA-N (2R)-2-chloro-3-methyloxirane Chemical compound CC1O[C@@H]1Cl LRWZZZWJMFNZIK-NFJMKROFSA-N 0.000 description 1
- FFYTTYVSDVWNMY-UHFFFAOYSA-N 2-Methyl-5-nitroimidazole Chemical class CC1=NC=C([N+]([O-])=O)N1 FFYTTYVSDVWNMY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940080526 mannitol injection Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses freeze dried levo-ornidazole powder for injection as one anaerobic bacteria infection resisting medicine. The freeze dried levo-ornidazole powder for injection includes levo-ornidazole as main medicinal component and pharmaceutically acceptable carrier, includes solvent selected from one or several of ethanol, propylene glycol, glycerin, polyethylene glycol, Tween-80, etc. The freeze dried levo-ornidazole powder for injection may be prepared into specification containing levo-ornidazole of 1-2000 mg, preferably 0.25-1.5g and especially 0.25g, 0.5g and 1.0g. It has high stability, high curative effect and other features.
Description
Technical field
The present invention relates to a kind of medicine, more particularly, the present invention relates to freezing-dried powder injection of a kind of anti anaerobic bacteria infection medicine laevo-ornidazole and preparation method thereof.
Background technology
Laevo-ornidazole is the levo form of ornidazole (Omidazole, CAS 16773-42-5), and its chemical name is 1-(3-chloro-2-hydroxypropyl)-2-methyl-5-nitro imidazoles, and molecular formula is C
7H
10ClN
2O
3, molecular weight is 219.6.
Ornidazole is a third generation nitro imidazole derivatives, is the medicine that a kind of powerful anaerobe resistant and protozoacide infect.The antibacterial action of ornidazole is to be reduced into amino by the nitro in the molecule in oxygen-free environment, or interacts by the formation and the cell component of free radical, thereby causes the death of microorganism.
At present, commercially available ornidazole preparation is a principal agent with the ornidazole raceme all.Clinically, ornidazole is used anti anaerobic bacteria infection report more, clinical effectiveness (Chinese Journal of New Drugs .2004 as ornidazole injection liquid treatment department of obstetrics and gynecology anaerobic infection, 13 (2) .158-160), ornidazole treatment oral cavity faciomaxillary region anaerobic infection paired observation (clinical stomatology magazine .2003,19 (7) .420-422) and ornidazole tablets treat clinical trial (Chinese Journal of New Drugs .2001,10 (11) .-833-836) of acute anaerobic infection disease and trichomonal vaginitis etc.Ornidazole has better curative effect aspect the treatment anaerobic infection, but also has untoward reaction simultaneously, mainly shows as central inhibitory action.
Chinese patent CN1400312A disclose a kind of utilize enzyme process from the mesotomy of ornidazole and prepare optically pure (S)-(-)-ornidazole or/and (R)-(+)-method of ornidazole.In the method, the raceme of ornidazole reacts the acetate that generates (S)-(-)-ornidazole with vinylacetate under the effect of chirality synthctic fat enzyme, this ester of purification, hydrolysis is converted into optically pure (S)-(-)-ornidazole, (R)-(+)-and ornidazole is not because react, can obtain by the purification mother solution; Perhaps elder generation is prepared into acetate with the raceme of ornidazole, make acetate under the effect of chirality synthctic fat enzyme, carry out selective hydrolysis and obtain optically pure (S)-(-)-ornidazole, (R)-(+)-and ornidazole then still exists with the form of acetate, and this acetate hydrolysis is converted into optically pure (R)-(+)-ornidazole.
Chinese patent application CN1651415A also discloses the method for a kind of preparation and purification ornidazole optical enantiomer, this method is under the catalytic action of Lewis acid, in the ethyl acetate solution of 2-methyl-5-nitro imidazoles, drip S-(+)-epoxychloropropane (or R-(-)-epoxychloropropane), then 5-10 ℃ of insulation reaction; The reactant of gained is hydrolyzed with frozen water, and the reactant liquor that obtains after the hydrolysis filters, and the filtrate standing demix adds acid after getting organic addition water again, standing demix, and it is mutually stand-by to fetch water; In aqueous phase solution, add ethyl acetate and weak base, standing demix; Get organic facies dehydrant drying, get crude product behind the concentrating under reduced pressure; Get finished product S-(+)-ornidazole (or R-(-)-ornidazole) with the organic solvent recrystallization.
Chinese patent application CN1686117A discloses the application of laevo-ornidazole at the preparation anti anaerobic bacteria infection medicine.The toxicity that discloses laevo-ornidazole in this patent is lower than dextrorotation and racemization ornidazole maincenter toxicity, and the drug effect basically identical; This patent also discloses a kind of oral formulations or intravenous injection of laevo-ornidazole, wherein, oral formulations is tablet or capsule, and intravenous injection is sodium chloride injection, glucose injection, sodium chloride-glucose injection, propylene glycol injection or formula mannitol injection liquid.
Chinese patent application CN1686116A then discloses intravenous administration formulation of a kind of laevo-ornidazole and preparation method thereof, wherein, intravenous administration formulation is the infusion preparation and the injection of laevo-ornidazole, and injection is the injection with small volume of propylene glycol, ethanol or Polyethylene Glycol.
Because laevo-ornidazole oral formulations drug effect is lower, and that infusion preparation, injection etc. exist at aspects such as transportation, preservations is inconvenient, and stability also can be affected, thus be necessary to provide a kind of injectable powder, to address these problems.But up to the present, do not see the report of levo-ornidazole freeze-dried powder injection and preparation method thereof in the prior art as yet.
Summary of the invention
The purpose of this invention is to provide a kind of levo-ornidazole freeze-dried powder injection;
Another object of the present invention has provided a kind of method for preparing levo-ornidazole freeze-dried powder injection.
On the one hand, according to technical scheme of the present invention, freezing-dried powder injection comprises as the laevo-ornidazole of principal agent and pharmaceutically acceptable carrier, wherein, for making principal agent soluble in water, can comprise cosolvent in the carrier, this cosolvent can be that choosing is taken from as next group one or more in material: ethanol, propylene glycol, glycerol, Polyethylene Glycol (PEG), Tween 80, nicotiamide, HP-, hydroxyethyl-, methyl-cyclodextrin, polyvinylpyrrolidone, lecithin, Ovum Gallus domesticus Flavus lecithin, sodium cholate, NaTDC and sodium dehydrocholate; Preferred cosolvent is one or more in propylene glycol, ethanol and the Polyethylene Glycol, and the amount of cosolvent is compared not little 1%ml/mg with the principal agent amount.
In levo-ornidazole freeze-dried powder injection of the present invention, its carrier can also contain the pH value regulator, and this pH value regulator can be to be selected from as next group one or more in material: hydrochloric acid, phosphoric acid, citric acid, acetic acid, lactic acid and tartaric acid.
In levo-ornidazole freeze-dried powder injection of the present invention, its carrier can also further comprise excipient, and this excipient can be to be selected from as next group one or more in material: dextran, mannitol, sucrose, glucose, fructose, lactose, cyclodextrin, microcrystalline Cellulose, soluble starch, pregelatinized Starch, sodium chloride, sodium bicarbonate, sodium carbonate, benzoic acid, sorbitol, citric acid and hydrolyzed protein.
In above-mentioned levo-ornidazole freeze-dried powder injection, principal agent and cosolvent weight ratio are 10: 0.1-5 is preferably 10: 0.2-1.0; Principal agent and excipient weight ratio are 10: 0.1-5, preferred 10: 0.5-2.
Levo-ornidazole freeze-dried powder injection of the present invention, its every bottle content specification can be 1-2000mg (in laevo-ornidazole), preferred 0.25-1.5g, especially preferred 0.25g, 0.5g or 1.0g.
On the other hand, the present invention also provides a kind of preparation method of levo-ornidazole freeze-dried powder injection, and it comprises the following steps:
A, preparating liquid: get laevo-ornidazole and drug acceptable carrier, add an amount of water for injection, fully stirring and dissolving adds with the PH regulator and adjusts PH to 3.5-5.0;
B, depyrogenation, degerming: add to the full amount of water for injection, add 0.05-0.3% (W/V) injection active carbon, stirred 20-30 minute, mixing is with 0.22 μ m filtering with microporous membrane degerming;
C, canned: select for use the control cillin bottle of appropriate size to carry out sterile filling;
D, lyophilizing: under cryogenic vacuum, carry out lyophilization.
Injection of the present invention has good stability, convenient transportation, and characteristics such as curative effect is good have better stability than liquid drugs injection.
Specific embodiments:
Further the present invention is illustrated below by embodiment.It should be understood that embodiments of the invention are to be used to illustrate the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
Embodiment 1
By following formulation levo-ornidazole freeze-dried powder injection.
Concrete prescription:
Laevo-ornidazole 250g
Dextran 50g
Propylene glycol 2500ml
Add the injection water to 3000ml
Make 1000 bottles of dried frozen aquatic productses altogether
Concrete steps are as follows:
Preparating liquid:
Take by weighing laevo-ornidazole, join in the propylene glycol, add an amount of water for injection, fully stirring and dissolving; The dextran that adds recipe quantity fully stirs in above-mentioned solution, adds to the full amount of water for injection, and stirs, with the hydrochloric acid conditioning solution PH to 4.0 of 0.1mol/L.
Depyrogenation, degerming:
The needle-use activated carbon that adds 0.1% (W/V) in above-mentioned solution stirred after 20～30 minutes, with 0.22 μ m filtering with microporous membrane degerming;
Fill:
(1) processing of control cillin bottle: select the control cillin bottle of 10ml, water is slightly washed during pretreatment, uses the purified water fine purifiation then, reuse water for injection fine purifiation, the cillin bottle of cleaning is thoroughly removed pyrogen through 220 ℃ of bakings in following 2 hours, and it is standby to be transferred to sterilizing room after reducing to 60 ℃.
(2) fill: carry out fill, the false add plug by drug specifications control loading amount;
Lyophilizing:
The stoppered product of dress false add moves in the special-purpose freeze drying box, below-40 ℃, about 2 hours of pre-freeze, evacuation is below the vacuum 13.33Pa (0.1mmHg), with 2～3 ℃/hour, after being warming up to 0 ℃, be warming up to 30 ℃, about 2 hours of heat preservation and dryness with 5～6 ℃/hour, automatic total head plug in the freeze drying box, outlet.
Gland:
The product of outlet is pressed aluminium lid through sterilizing immediately, promptly get levo-ornidazole freeze-dried powder injection.
Embodiment 2
By following formulation levo-ornidazole freeze-dried powder injection.
Concrete prescription:
Laevo-ornidazole 125g
Mannitol 25g
Propylene glycol 1250ml
Add the injection water to 2000ml
Make 1000 bottles of dried frozen aquatic productses altogether
Concrete steps are as follows:
Preparating liquid:
Take by weighing laevo-ornidazole, join in the propylene glycol, add an amount of water for injection, fully stirring and dissolving; The mannitol that adds recipe quantity fully stirs in above-mentioned solution, adds to the full amount of water for injection, and stirs, with the hydrochloric acid conditioning solution PH to 4.0 of 0.1mol/L.
Depyrogenation, degerming:
The needle-use activated carbon that adds 0.1% (W/V) in above-mentioned solution stirred after 20～30 minutes, with 0.22 μ m filtering with microporous membrane degerming;
Fill:
(1) processing of control cillin bottle: select the control cillin bottle of 7ml, water is slightly washed during pretreatment, uses the purified water fine purifiation then, reuse water for injection fine purifiation, the cillin bottle of cleaning is thoroughly removed pyrogen through 220 ℃ of bakings in following 2 hours, and it is standby to be transferred to sterilizing room after reducing to 60 ℃.
(2) fill: carry out fill, the false add plug by drug specifications control loading amount;
Lyophilizing:
The stoppered product of dress false add moves in the special-purpose freeze drying box, below-40 ℃, about 2 hours of pre-freeze, evacuation is below the vacuum 13.33Pa (0.1mmHg), with 2～3 ℃/hour, after being warming up to 0 ℃, be warming up to 30 ℃, about 2 hours of heat preservation and dryness with 5～6 ℃/hour, automatic total head plug in the freeze drying box, outlet.
Gland:
The product of outlet is pressed aluminium lid through sterilizing immediately, promptly get levo-ornidazole freeze-dried powder injection.
Embodiment 3
By following formulation levo-ornidazole freeze-dried powder injection.
Concrete prescription:
Laevo-ornidazole 250g
Dextran 50g
Polyethylene Glycol 100g
Add the injection water to 2000ml
Make 1000 bottles of dried frozen aquatic productses altogether
Concrete steps are as follows:
Preparating liquid:
Take by weighing laevo-ornidazole and Polyethylene Glycol, join in the water for injection of about 1600ml, fully stir and make its dissolving, the dextran that adds recipe quantity then is in above-mentioned solution, and stirring and dissolving adds to the full amount of water for injection, stir, with the hydrochloric acid conditioning solution PH to 4.0 of 0.1mol/L.
Depyrogenation, degerming:
The needle-use activated carbon that adds 0.1% (W/V) in above-mentioned solution stirred after 20～30 minutes, with 0.22 μ m filtering with microporous membrane degerming;
Fill:
(1) processing of control cillin bottle: select the control cillin bottle of 7ml, water is slightly washed during pretreatment, uses the purified water fine purifiation then, reuse water for injection fine purifiation, the cillin bottle of cleaning is thoroughly removed pyrogen through 220 ℃ of bakings in following 2 hours, and it is standby to be transferred to sterilizing room after reducing to 60 ℃.
(2) fill: carry out fill, the false add plug by drug specifications control loading amount;
Lyophilizing:
The stoppered product of dress false add moves in the special-purpose freeze drying box, below-40 ℃, about 2 hours of pre-freeze, evacuation is below the vacuum 13.33Pa (0.1mmHg), with 2～3 ℃/hour, after being warming up to 0 ℃, be warming up to 30 ℃, about 2 hours of heat preservation and dryness with 5～6 ℃/hour, automatic total head plug in the freeze drying box, outlet.
Gland:
The product of outlet is pressed aluminium lid through sterilizing immediately, promptly get levo-ornidazole freeze-dried powder injection.
Embodiment 4
By following formulation levo-ornidazole freeze-dried powder injection.
Concrete prescription:
Laevo-ornidazole 500g
Mannitol 80g
Macrogol 200 g
Add the injection water to 4000ml
Make 1000 bottles of dried frozen aquatic productses altogether
Concrete steps are as follows:
Preparating liquid:
Take by weighing laevo-ornidazole and Polyethylene Glycol, join in the water for injection of about 3500ml, fully stir and make its dissolving, the mannitol that adds recipe quantity then is in above-mentioned solution, and stirring and dissolving adds to the full amount of water for injection, stir, with the tartaric acid regulator solution PH to 4.0 of 0.1mol/L.
Depyrogenation, degerming:
The needle-use activated carbon that adds 0.1% (W/V) in above-mentioned solution stirred after 20～30 minutes, with 0.22 μ m filtering with microporous membrane degerming;
Fill:
(1) processing of control cillin bottle: select the control cillin bottle of 15ml, water is slightly washed during pretreatment, uses the purified water fine purifiation then, reuse water for injection fine purifiation, the cillin bottle of cleaning is thoroughly removed pyrogen through 220 ℃ of bakings in following 2 hours, and it is standby to be transferred to sterilizing room after reducing to 60 ℃.
(2) fill: carry out fill, the false add plug by drug specifications control loading amount;
Lyophilizing:
The stoppered product of dress false add moves in the special-purpose freeze drying box, below-40 ℃, about 2 hours of pre-freeze, evacuation is below the vacuum 13.33Pa (0.1mmHg), with 2～3 ℃/hour, after being warming up to 0 ℃, be warming up to 30 ℃, about 2 hours of heat preservation and dryness with 5～6 ℃/hour, automatic total head plug in the freeze drying box, outlet.
Gland:
The product of outlet is pressed aluminium lid through sterilizing immediately, promptly get levo-ornidazole freeze-dried powder injection.
Embodiment 5
By following formulation levo-ornidazole freeze-dried powder injection.
Concrete prescription:
Laevo-ornidazole 125g
Mannitol 25g
Ethanol 1000ml
Tween 80 250ml
Add the injection water to 2000ml
Make 1000 bottles of dried frozen aquatic productses altogether
Concrete steps are as follows:
Preparating liquid:
Get the recipe quantity Tween 80, join in about 500ml water for injection, fully stir and make its dissolving; Other gets laevo-ornidazole, joins in the ethanol, fully stirs and makes its dissolving.
Above-mentioned two kinds of solution are mixed, stir, add the mannitol of recipe quantity then, fully stir, add to the full amount of water for injection, with the hydrochloric acid conditioning solution PH to 4.0 of 0.1mol/L.
Depyrogenation, degerming:
The needle-use activated carbon that adds 0.1% (W/V) in above-mentioned solution stirred after 20～30 minutes, with 0.22 μ m filtering with microporous membrane degerming;
Fill:
(1) processing of control cillin bottle: select the control cillin bottle of 5ml, water is slightly washed during pretreatment, uses the purified water fine purifiation then, reuse water for injection fine purifiation, the cillin bottle of cleaning is thoroughly removed pyrogen through 220 ℃ of bakings in following 2 hours, and it is standby to be transferred to sterilizing room after reducing to 60 ℃.
(2) fill: carry out fill, the false add plug by drug specifications control loading amount;
Lyophilizing:
The stoppered product of dress false add moves in the special-purpose freeze drying box, below-40 ℃, about 2 hours of pre-freeze, evacuation is below the vacuum 13.33Pa (0.1mmHg), with 2～3 ℃/hour, after being warming up to 0 ℃, be warming up to 30 ℃, about 2 hours of heat preservation and dryness with 5～6 ℃/hour, automatic total head plug in the freeze drying box, outlet.Gland:
The product of outlet is pressed aluminium lid through sterilizing immediately, promptly get levo-ornidazole freeze-dried powder injection.
Claims (10)
1, a kind of levo-ornidazole freeze-dried powder injection, it is characterized in that, this freezing-dried powder injection comprises as the laevo-ornidazole of principal agent and pharmaceutically acceptable carrier, wherein, comprise cosolvent in the described carrier, described cosolvent is to be selected from as next group one or more in material: ethanol, propylene glycol, glycerol, Polyethylene Glycol, Tween 80, nicotiamide, HP-, hydroxyethyl-, methyl-cyclodextrin, polyvinylpyrrolidone, lecithin, Ovum Gallus domesticus Flavus lecithin, sodium cholate, NaTDC and sodium dehydrocholate.
2, freezing-dried powder injection as claimed in claim 1, it is characterized in that, described carrier also comprises excipient, and described excipient is to be selected from as next group one or more in material: dextran, mannitol, sucrose, glucose, fructose, lactose, cyclodextrin, microcrystalline Cellulose, soluble starch, pregelatinized Starch, sodium chloride, sodium bicarbonate, sodium carbonate, benzoic acid, sorbitol, citric acid and hydrolyzed protein.
3, freezing-dried powder injection as claimed in claim 2, it is characterized in that, described carrier also comprises the pH value regulator, and described pH value regulator is to be selected from as next group one or more in material: hydrochloric acid, phosphoric acid, citric acid, acetic acid, lactic acid and tartaric acid.
4, freezing-dried powder injection as claimed in claim 2 is characterized in that, described principal agent and described excipient weight ratio are 10: 0.1-5.
5, freezing-dried powder injection as claimed in claim 4 is characterized in that, described principal agent and described excipient weight ratio are 10: 0.5-2.
As the described freezing-dried powder injection of claim 1-5, it is characterized in that 6, described cosolvent is to be selected from propylene glycol, ethanol and the Polyethylene Glycol one or more.
7, freezing-dried powder injection as claimed in claim 6 is characterized in that, with respect to described principal agent, the amount of described cosolvent is not less than 1%ml/mg.
8, freezing-dried powder injection as claimed in claim 7 is characterized in that, described principal agent and described cosolvent weight ratio are 10: 0.1-5.
9, freezing-dried powder injection as claimed in claim 8 is characterized in that, described principal agent and described cosolvent weight ratio are 10: 0.2-1.0.
10, a kind of preparation is as the method for one of claim 1-9 described freezing-dried powder injection, and this method comprises the following steps:
A, preparating liquid: get laevo-ornidazole and pharmaceutically acceptable carrier, add an amount of water for injection, fully stirring and dissolving adds with the PH regulator and adjusts PH to 3.5-5.0;
B, depyrogenation, degerming: add to the full amount of water for injection, add the injection active carbon, stirring, mixing, and use the filtering with microporous membrane degerming;
C, canned: select for use the control cillin bottle of appropriate size to carry out sterile filling;
D, lyophilizing: under cryogenic vacuum, carry out lyophilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510102377 CN1820748A (en) | 2005-12-19 | 2005-12-19 | Levo-ornidazole freeze-dried powder injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510102377 CN1820748A (en) | 2005-12-19 | 2005-12-19 | Levo-ornidazole freeze-dried powder injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1820748A true CN1820748A (en) | 2006-08-23 |
Family
ID=36922419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510102377 Pending CN1820748A (en) | 2005-12-19 | 2005-12-19 | Levo-ornidazole freeze-dried powder injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1820748A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100463677C (en) * | 2007-02-13 | 2009-02-25 | 江苏奥赛康药业有限公司 | Preparation of nedaplatin freeze-dried powder injection |
| CN102552127A (en) * | 2012-01-31 | 2012-07-11 | 石家庄开发区博欣医药科技开发有限公司 | Ornidazole injection |
| CN103040740A (en) * | 2013-01-25 | 2013-04-17 | 山西普德药业股份有限公司 | Ornidazole injection and preparation technology thereof |
| CN104404002A (en) * | 2014-12-12 | 2015-03-11 | 江苏省农业科学院 | Composition for improving infection efficiency of porcine circovirus type 2, and application of composition |
| CN110638761A (en) * | 2018-06-08 | 2020-01-03 | 上海莫息生物科技有限公司 | Avermemycin soluble powder and preparation method thereof |
| CN113797165A (en) * | 2021-09-30 | 2021-12-17 | 南京瑞捷医药科技有限公司 | Ornidazole injection |
-
2005
- 2005-12-19 CN CN 200510102377 patent/CN1820748A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100463677C (en) * | 2007-02-13 | 2009-02-25 | 江苏奥赛康药业有限公司 | Preparation of nedaplatin freeze-dried powder injection |
| CN102552127A (en) * | 2012-01-31 | 2012-07-11 | 石家庄开发区博欣医药科技开发有限公司 | Ornidazole injection |
| CN103040740A (en) * | 2013-01-25 | 2013-04-17 | 山西普德药业股份有限公司 | Ornidazole injection and preparation technology thereof |
| CN104404002A (en) * | 2014-12-12 | 2015-03-11 | 江苏省农业科学院 | Composition for improving infection efficiency of porcine circovirus type 2, and application of composition |
| CN104404002B (en) * | 2014-12-12 | 2017-06-30 | 江苏省农业科学院 | Composition and its application for improving porcine circovirus type 2 infection efficiency |
| CN110638761A (en) * | 2018-06-08 | 2020-01-03 | 上海莫息生物科技有限公司 | Avermemycin soluble powder and preparation method thereof |
| CN110638761B (en) * | 2018-06-08 | 2022-05-24 | 上海莫息生物科技有限公司 | Avermectin soluble powder and preparation method thereof |
| CN113797165A (en) * | 2021-09-30 | 2021-12-17 | 南京瑞捷医药科技有限公司 | Ornidazole injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1147472C (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
| CN1091368C (en) | Pharmaceutical composition comprising coenzyme Q10 | |
| CN1084408A (en) | Cyclic adhesion inhibitors | |
| CN1010279B (en) | Preparation method of injection pharmaceutical composition containing sperguanidine flexible components | |
| CN1568999A (en) | Stable freeze dried formulation of spheroidine for medical use | |
| CN1820748A (en) | Levo-ornidazole freeze-dried powder injection | |
| CN1792362A (en) | Intravenous administration preparation of arbidol and salt thereof and preparation method | |
| CN1225464C (en) | Extraction process, medicinal composition and preparation process of wogonin | |
| CN1557812A (en) | Potassium sodium dehydroandroandrographolide succinates and their preparations | |
| CN1197572C (en) | Hypoalbuminemia improvement agent | |
| CN1788725A (en) | Voriconazole freeze-drying powder injection and its preparation process | |
| CN1101189C (en) | Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient | |
| CN1263736C (en) | Solution of tetrahydrate N-[ortho-(para-trimethyl acetoxyl benzenesulfonamide) benzoyl] glycine monosodium salt and its medicine | |
| CN1651433A (en) | A kind of salvianolic acid berberine double salt and its preparation method and application | |
| CN1709248A (en) | Lansoprazole lyophilized powder injection and its preparing method | |
| CN1626085A (en) | Levosimendan freeze-dried preparation and preparing method | |
| CN1739505A (en) | L-ornidazole injection prepn | |
| CN1543943A (en) | Oral silymarin sustained-release preparation and preparation method thereof | |
| CN1555805A (en) | Ortho diphenylhydratoin freeze dried powder for injection and its preparation method | |
| CN1309125A (en) | Composition of gambogic acid compounds with anticancer activity and its preparing process | |
| CN1080851A (en) | The reinforcing agent of somatostatin | |
| CN1186094C (en) | Piracetam medicine composition with function of promoting thinking and memory and its prepn | |
| CN1183908C (en) | Injection medication combination of nimodipine and its preparing method | |
| CN1903869A (en) | Tibifudine derivative salt and its preparation method and pharmaceutical application | |
| CN1557477A (en) | Sterile and freeze dried hypophysin preparation for injection and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |